Oct 29 (Reuters) - Grifols SA:
* SAID ON SATURDAY THAT AMBAR CLINICAL TRIAL DEMONSTRATED THE ABILITY TO SLOW DOWN THE PROGRESSION OF THE DISEASE IN MODERATE ALZHEIMER’S DISEASE (AD) PATIENTS
* THE RESULTS IN THE PRESPECIFIED COHORT OF THE PATIENTS SHOWED A REDUCTION OF 61% IN DISEASE PROGRESSION IN BOTH PRIMARY EFFICACY ENDPOINTS MEASURING COGNITION AND ACTIVITIES OF DAILY LIVING DURING A 14 MONTH PERIOD
* AMBAR (ALZHEIMER MANAGEMENT BY ALBUMIN REPLACEMENT) AIMS TO EVALUATE WHETHER AD CAN BE STABILIZED BY PERIODICALLY EXTRACTING PLASMA AND REPLACING IT WITH ALBUMIN
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.